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(Aldomet) in our LC-MS/MS method for urinary metanephrine analysis. A 36-year-old woman was referred to our hospital for diagnostic work-up of her hypertension. She had been successfully treated with AMD for hypertension during pregnancy. Postpartum, after initial normalization, her blood pressure increased despite the use of AMD. Her normetanephrine value of 19.2 μmol/24 h was >6 times the upper reference limit (0.4 -3.0 μmol/L/24 h), with metanephrine being only slightly increased (1.5 μmol/24 h; reference value 0.1-1.1 μmol/24 h), as measured by ultra-performance liquid chromatography (UPLC)-MS/MS (Quattro Premier XE Mass Spectrometer, Waters). Her physician reported that she was taking AMD, an indirect-acting α-anticholinergic receptor blocker, which is indicated treatment for gestational hypertension. AMD is known for analytical interference in HPLC methods for metanephrine measurement, but, at present, it is unclear whether analytical interference from AMD also holds for LC-MS/MS. A closer inspection of the mass spectrometry (MS) data made clear that a closely eluting peak had been mistakenly integrated by the MS instrument software (Quanlynx, Waters) as being normetanephrine (Fig. 1, left panel) . Furthermore, the software normalizes the highest, in this case interfering, peak within a specified retention time (Rt) window to 100%, resulting in a minor normetanephrine peak (Fig. 1,  left panel) . In retrospect, 2 aspects should have raised suspicion of assay interference. First, the interfering peak displayed a slightly earlier Rt (1.30 min) when compared to the stable isotopically labeled internal standard (d 3 -normetanephrine) (Rt 1.40 min), as well as to other patient samples in the series. Second, the software gave notification of a quantifier/qualifier ratio failure [m/z 166 > 106 (quantifier)/m/z 166 > 134 (qualifier) ratio was 1.60 (normal 0.80 (± 0.16)]. Quantification of the true normetanephrine signal (Fig. 1, left panel) revealed a normal value of 0.7 μmol/24 h (ion ratio 0.83), thereby more or less excluding a diagnosis of pheochromocytoma. To confirm the use of AMD as being the cause of the interference, AMD was withheld for 8 weeks and then urinary metanephrines were reanalyzed. The interfering signal had disappeared, resulting in a normal normetanephrine value of 1.2 μmol/24 h (Fig. 1, right  panel) . Urine normetanephrine analysis of a second patient on AMD showed the same interfering peak in our LC-MS/MS assay (result not shown).
AMD (M r 211) is known to become decarboxylated to α-methyldopamine (M r 167) by aromatic L-amino acid decarboxylase with subsequent oxidative hydroxylation by dopamine-β-hydroxylase to α-methylnorepinephrine (M r 183) (Fig. 1, bottom) . α-Methylnorepinephrine and normetanephrine are isomers, with the same molecular formula but different structures. In the positive mode, normetanephrine is pro- ............................................................................................. .. Subsequent normetanephrine analysis of urine samples spiked with various concentrations of either AMD or α-methylnorepinephrine (up to 0.5 mmol/L) did, however, not result in the interfering compound, as was found in the patient taking AMD. Analytical interference from other AMD metabolites (for example, α-methyldopamine) has not been tested and therefore cannot be ruled out.
Our LC-MS/MS method for urinary metanephrine analysis uses a hydrophilic interaction liquid chromatography (HILIC) analytical column (BEH HILIC, Waters) and an acetonitrile/water gradient. Normetanephrine interferences were absent when urine samples were reanalyzed by our plasma LC-MS/MS method, which uses a reversedphase column (HSS T3, Waters) and methanol/water gradient. Hence, analytical interference of AMD with LC-MS/MS measurement of normetanephrine appears to depend on the column type and/or chromatographic conditions. From now on, we will use a reversed-phase column for both urine and plasma metanephrine analysis.
We believe that AMD should be added to the list of drugs that may interfere with (nor)-metanephrine analysis in urine or plasma by LC-MS/MS and preferably be discontinued before testing (2) (3) (4) (5) . Our finding emphasizes the importance of critical evaluation of each chromatogram and notification of ion ratio failure. Therefore, despite allegedly exquisite specificity, LC-MS/MS can indeed be susceptible to analytical interferences that can lead to falsepositive results in metanephrine measurement. This result is particularly so for compounds with unresolvable mass fragmentation, where chromatography remains key to guaranteeing accurate patient results (3).
